Drug intelligence / Profile preview

drotaverine + ibuprofen

Development stage
Unknown
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

A fixed-dose combination drug containing **drotaverine**, an antispasmodic agent (phosphodiesterase 4 inhibitor), and **ibuprofen**, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory action. The combination is formulated to provide both relief from smooth muscle spasms and pain, particularly effective in conditions such as menstrual cramps (dysmenorrhea) and abdominal spasms. Drotaverine acts by selectively inhibiting phosphodiesterase 4 (PDE4), relaxing smooth muscle without anticholinergic effects, while ibuprofen inhibits cyclooxygenase (COX) enzymes to decrease prostaglandin synthesis, reducing inflammation and pain[1][3][4]. The combination may be available as a monolithic or bilayer tablet developed for improved patient compliance and enhanced efficacy in pain management[4].

Brand names
Algoflex-M
Other names
drotaverine hydrochloride + ibuprofen
02

Targets

PDE4 (Phosphodiesterase 4A1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on drotaverine + ibuprofen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on drotaverine + ibuprofen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call